2 large 48-wk phase 3 trials (Be HEARD I/II) of Bimekizumab vs PBO in moderate-to-severe hidradenitis suppurativa shows BKZ to be safe & significantly effective (48% vs 29% & 52% vs 32%) vs PBO. https://t.co/xPXUd9vHyE https://t.co/uESOGYhAdw
Links:
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidraden…
https://buff.ly/4dXL8wh
May-29-2024
